当前位置: X-MOL 学术Curr. Opin. Pharmacol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Fecal microbiota transplantation as a new therapy: from Clostridioides difficile infection to inflammatory bowel disease, irritable bowel syndrome, and colon cancer
Current Opinion in Pharmacology ( IF 4.0 ) Pub Date : 2019-06-05 , DOI: 10.1016/j.coph.2019.04.017
Thomas J Borody , Guy D Eslick , Robert L Clancy

Fecal microbiota transplantation (FMT) represents the most effective means of therapeutically manipulating the gastrointestinal microbiome. Originally employed as a treatment of last-resort in patients with life-threatening Clostridioides difficile infection (CDI), FMT gained widespread acceptance during the CDI epidemic, where it achieved resolution rates approaching 100%. Following our newfound appreciation for the role of the gut microbiome in both health and disease and owing to FMT’s unique mechanism/s of action, FMT is rapidly advancing as an effective treatment for a number of conditions in which the gastrointestinal microbiome is thought to play a role. We review the role of FMT from its beginnings in CDI to its expansion into inflammatory bowel disease, irritable bowel syndrome, and colon cancer.



中文翻译:

粪便菌群移植作为一种新疗法:从艰难梭菌感染到炎症性肠病,肠易激综合症和结肠癌

粪便微生物群移植(FMT)代表了治疗性操作胃肠道微生物组的最有效手段。FMT最初是用于危及生命的艰难梭菌Clostridioides difficile)感染(CDI)患者的最后治疗方法,在CDI流行期间,FMT得到了广泛的接受,其解决率接近100%。由于我们对肠道微生物组在健康和疾病中的作用有了新发现,并且由于FMT独特的作用机制,FMT正迅速发展成为一种有效的治疗方法,可用于治疗许多认为胃肠道微生物组起着重要作用的疾病。角色。我们回顾了FMT从其在CDI开始到其扩展为炎性肠病,肠易激综合症和结肠癌的作用。

更新日期:2019-06-05
down
wechat
bug